Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O — CHAZESubstrate

Atrial Fibrillation (AF) Clinical Trial

Official title:
Characterization of Left Atrial Substrate by Comparison of Bipolar Voltage Maps With Standard Focal 4.5 mm Tip Electrode, 1 mm Ring Electrode, and Microelectrode Catheters Using InTEllaMap Orion and IntellaNav MIFI O

Status Completed

Clinical Trial Summary

This study is to investigate the correlation and to obtain the coefficient of correlation between the global and local bipolar signals (voltage maps) of the LA in sinus rhythm using a focal 4.5 mm irrigated-tip ablation catheter (in combination with microelectrodes), a ring-electrode circular mapping catheter and a microelectrode multipolar catheter in combination with the Rhythmia system.

Clinical Trial Description

Current hypothesis of the mechanism of atrial fibrillation (AF) is a combination of local firing mainly triggered from the pulmonary veins and atrial substrate due to atrial remodelling sustaining AF. Whereas for paroxysmal AF, pulmonary vein isolation (PVI) is still the mainstay of interventional treatment, a left atrial (LA) substrate-based ablation especially in patients with persistent or long-standing persistent AF may be reasonable to improve freedom from AF. In addition, even in patients with paroxysmal AF, substrate-based ablation strategies have been shown to improve outcome. Substrate characterization of the LA is currently performed using the focal ablation catheter with a 3.5mm irrigated tip catheter with a 2 mm interelectrode spacing, a circular (Lasso) or spider like diagnostic (Pentaray) catheter with 1 mm size of the ring electrodes and 2 mm to 4 mm interelectrode spacing. Consequently, the cut-off values to delineate healthy tissue from diseased substrate are defined based on these measures. Since the electrode size and distance between the electrodes determines the bipolar voltage amplitude and morphology (beside their orientation with regard to the propagation wavefront), differences in bipolar voltage values must be expected between different catheter types and especially for the novel micro-electrode catheters IntellaMap Orion and IntellaNav MIFI OI. With the knowledge of the relationship between the bipolar voltage maps created with the different catheter types, information/knowledge from one study obtained with a specific catheter can be transferred to patients treated with the other catheter types. This study is to investigate the correlation and to obtain the coefficient of correlation between the global and local bipolar signals (voltage maps) of the LA in sinus rhythm using a focal 4.5 mm irrigated-tip ablation catheter (in combination with microelectrodes), a ring-electrode circular mapping catheter and a microelectrode multipolar catheter in combination with the Rhythmia system. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04095559
Study type	Observational
Source	University Hospital, Basel, Switzerland
Contact
Status	Completed
Phase
Start date	December 5, 2019
Completion date	May 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02630914` - Medical and Surgical Hybrid Treatment of Atrial Fibrillation.	N/A
Completed	`NCT05410379` - Antral Lesions Characterization of a New Cryoballoon Ablation System in Terms of Local Impedance Drop
Enrolling by invitation	`NCT05407415` - KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation	N/A
Completed	`NCT04025710` - Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)	N/A
Completed	`NCT01119274` - EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon	Phase 4
Recruiting	`NCT03428048` - Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.
Recruiting	`NCT04298723` - Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.	N/A
Completed	`NCT04218266` - Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.	Phase 2
Active, not recruiting	`NCT03732794` - AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment	N/A
Active, not recruiting	`NCT04755283` - Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation	Phase 2
Recruiting	`NCT05712200` - Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)	Phase 3
Recruiting	`NCT05955365` - Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation	Phase 4
Recruiting	`NCT05294445` - From the Emergency Department Directly to Ablation of Atrial Fibrillation Study	N/A
Completed	`NCT02513316` - Clinical Relevance of Microbleeds In Stroke	N/A
Completed	`NCT04809922` - Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.